Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Recruiting · NCT06361316 · Interventional (participants receive a specific treatment) · Lead sponsor: Kuirong Jiang
View the official record on ClinicalTrials.gov →Interventions studied
Irinotecan liposome injection
What this trial is about
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- ECOG performance status 0 or 1.
- Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
- ECOG performance status 0 or 1.
- Life expectancy of greater than or equal to 6 months.
- Able and willing to provide a written informed consent.
Exclusion criteria
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
Where it is running
1 location listed.
- FirstNanjingMU - Nanjing, Jiangsu, China